Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services. The company offers its products under the name of Pro-Dex.Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone949-769-3231
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.47 million
Profitability
Miscellaneous
Employees80
Next Earnings Date9/12/2019 (Estimated)
OptionableNot Optionable
Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions
What is Pro-Dex's stock symbol?
Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."
How were Pro-Dex's earnings last quarter?
Pro-Dex Inc (NASDAQ:PDEX) released its quarterly earnings data on Thursday, August, 30th. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.16. Pro-Dex had a return on equity of 19.69% and a net margin of 12.98%. View Pro-Dex's Earnings History.
When is Pro-Dex's next earnings date?
What price target have analysts set for PDEX?
1 equities research analysts have issued 12 month price objectives for Pro-Dex's stock. Their predictions range from $20.00 to $20.00. On average, they anticipate Pro-Dex's stock price to reach $20.00 in the next year. This suggests a possible upside of 41.9% from the stock's current price. View Analyst Price Targets for Pro-Dex.
What is the consensus analysts' recommendation for Pro-Dex?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pro-Dex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pro-Dex.
Has Pro-Dex been receiving favorable news coverage?
News coverage about PDEX stock has been trending positive this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pro-Dex earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for Pro-Dex.
Are investors shorting Pro-Dex?
Pro-Dex saw a decrease in short interest in the month of July. As of July 15th, there was short interest totalling 12,600 shares, a decrease of 36.7% from the June 15th total of 19,900 shares. Based on an average daily volume of 25,900 shares, the short-interest ratio is presently 0.5 days. Currently, 0.4% of the shares of the stock are sold short. View Pro-Dex's Current Options Chain.
Who are some of Pro-Dex's key competitors?
Some companies that are related to Pro-Dex include Vapotherm (VAPO), SeaSpine (SPNE), Soliton (SOLY), Neuronetics (STIM), Cytosorbents (CTSO), RenovaCare (RCAR), Repro-Med Systems (REPR), iCAD (ICAD), BRAINSWAY LTD/S (BWAY), Sensus Healthcare (SRTS), Liquidia Technologies (LQDA), Endologix (ELGX), Motus GI (MOTS), Apollo Endosurgery (APEN) and Spectral Medical (EDTXF).
What other stocks do shareholders of Pro-Dex own?
Who are Pro-Dex's key executives?
Pro-Dex's management team includes the folowing people:
- Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 58)
- Mrs. Alisha K. Charlton, CFO & Corp. Sec. (Age 49)
Who are Pro-Dex's major shareholders?
Pro-Dex's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (2.23%), Vanguard Group Inc. (2.03%), Alambic Investment Management L.P. (1.63%), BlackRock Inc. (1.54%), Municipal Employees Retirement System of Michigan (0.73%) and Marshall Wace LLP (0.61%). Company insiders that own Pro-Dex stock include Alisha Charlton, David Hovda, Kirk Richard Lee Van Jr, Nicholas John Swenson, Raymond E Cabillot and William James Farrell III. View Institutional Ownership Trends for Pro-Dex.
Which major investors are selling Pro-Dex stock?
PDEX stock was sold by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P. and Wells Fargo & Company MN. Company insiders that have sold Pro-Dex company stock in the last year include Alisha Charlton, David Hovda, Kirk Richard Lee Van Jr, Nicholas John Swenson and Raymond E Cabillot. View Insider Buying and Selling for Pro-Dex.
Which major investors are buying Pro-Dex stock?
PDEX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Municipal Employees Retirement System of Michigan, Marshall Wace LLP, Seizert Capital Partners LLC, Wedge Capital Management L L P NC, Acadian Asset Management LLC and Vanguard Group Inc.. Company insiders that have bought Pro-Dex stock in the last two years include Kirk Richard Lee Van Jr and William James Farrell III. View Insider Buying and Selling for Pro-Dex.
How do I buy shares of Pro-Dex?
Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pro-Dex's stock price today?
One share of PDEX stock can currently be purchased for approximately $14.09.
How big of a company is Pro-Dex?
What is Pro-Dex's official website?
How can I contact Pro-Dex?
Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3231 or via email at [email protected]
MarketBeat Community Rating for Pro-Dex (NASDAQ PDEX)
MarketBeat's community ratings are surveys of what our community members think about Pro-Dex and other stocks. Vote "Outperform" if you believe PDEX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDEX will underperform the S&P 500 over the long term. You may vote once every thirty days.
